The 778-subject PROGRESS trial tested Qulipta in migraine patients who had been experiencing headache on 15 or more days per month, for at least three months, with AbbVie's drug given as either 60 ...

AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy. Botox is prescribed for the prevention of headaches in adults diagnosed ...

AbbVie reported that sales from Ubrelvy and a similar migraine medication called Qulipta, generated $1.223billion in revenue for the company in 2023. This is not the first time the agency has ...